ICH Aims For Drug Quality Standards That Promote Continual Improvement, New Technology
Executive Summary
ICH quality reflection paper outlines slate of guidelines to be adopted in near future, as well as a longer-term focus on training and implementation of its guidelines among a growing list of member countries around the world.
You may also be interested in...
US FDA Sees Slow But Steady Progress In Adoption Of Continuous Manufacturing
The COVID-19 pandemic has prompted the ICH to delay by six months its efforts to develop Q13 guideline on continuous manufacturing, now not expected until May 2022.
ICH Quality Discussion Group Canvasses Members, Prepares Additional Guideline Proposals
The ICH Informal Quality Discussion Group considers an array of proposed new and revised quality guidelines and asks members for additional ideas.
The Quality Lowdown: Diversion, Cross-Contamination And PR Mix-Ups
McKesson meets with US FDA over opioid diversion warning letter, while UK MHRA takes risk-based approach to cross-contamination recalls and firm says it’s the other Guardian Pharmacy.